Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1140209

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cystic Fibrosis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent discussions there have been between Vertex Pharmaceuticals and NHS England with on cystic fibrosis medicines.
	tabling member constituency	Bristol East
	tabling member printed	Kerry McCarthy
	uin	278928
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>Discussions with Vertex, including meetings, are ongoing.</p><p>NHS England and NHS Improvement are leading the negotiations with Vertex and have made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients.</p><p>The Government fully supports NICE, NHS England and NHS Improvement in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England’s and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 278929 question first answered 23/07/2019 16:49:59 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1491 label Biography information for Kerry McCarthy

1140210

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cystic Fibrosis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will set a deadline for NHS England and Vertex Pharmaceuticals to come to an agreement to enable access to cystic fibrosis medicines produced by that company.
	tabling member constituency	Bristol East
	tabling member printed	Kerry McCarthy
	uin	278929
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>Discussions with Vertex, including meetings, are ongoing.</p><p>NHS England and NHS Improvement are leading the negotiations with Vertex and have made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients.</p><p>The Government fully supports NICE, NHS England and NHS Improvement in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England’s and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 278928 question first answered 23/07/2019 16:49:59 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1491 label Biography information for Kerry McCarthy

1129402

	registered interest
	date	03/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Prices
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the Government’s decision to not support the World Health Assembly's resolution on greater transparency for drug pricing on the affordability of medicines in the UK.
	tabling member constituency	Bristol East
	tabling member printed	Kerry McCarthy
	uin	259098
	answer	answer is ministerial correction date of answer 06/06/2019 answer text <p>The United Kingdom participates in various transparency initiatives, including the European Integrated Price Information Database, the World Health Organization’s Pharmaceutical Pricing Reimbursement Information Network, and the Global Fund Price and Quality Database. However, the UK has a long-established and globally-recognised track record of assessing the price of new, innovative medicines according to their clinical value, rather than pricing by their development costs or international reference prices. We believe that is the right approach: ensuring the development of the best medicines in areas of high unmet need are rewarded. The Government could not, therefore, agree to a resolution which had the potential to increase medicines prices and reduce patient access, by reducing the ability of the NHS to undertake commercial negotiations with pharmaceutical companies on the price of new medicines. The approach taken by the National Health Service has meant we were the first country in Europe to offer innovative CAR-T therapies, alongside many other new medicines.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 06/06/2019 15:58:52 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1491 label Biography information for Kerry McCarthy